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Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in the
western hemisphere. It is characterized by a clonal proliferation of a population of CD5+
B lymphocytes that accumulate in the secondary lymphoid tissues, bone marrow, and
blood. Some CLL patients remain free of symptoms for decades, whereas others rapidly
become symptomatic or develop high-risk disease. Studying autophagy, which may
modulate key protein expression and cell survival, may be important to the search for
novel prognostic factors and molecules. Here, we applied flow cytometry technology
to simultaneously detect autophagy protein LC3B with classical phenotypical markers
used for the identification of tumoral CLL B cell clones. We found that two patients
with progressing CLL showed increased expression of the autophagy protein LC3B, in
addition to positive expression of CD38 and ZAP70 and unmutated status of IGHV. Our
data suggest that activation of autophagy flux may correlate with CLL progression even
before Ibrutinib treatment.
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) represents 25% of all leukemias and 1.3% of all cancers in the
western hemisphere, but it has lower prevalence in Asia (1, 2). It is characterized by the expansion
of a population of monoclonal CD5+ B lymphocytes that accumulate in blood, bone marrow, and
secondary lymphoid tissues (3, 4). Chronic lymphocytic leukemia frequently presents with adverse
prognostic features in older patients, significantly affecting their survival (1).
The average age at the time of diagnosis is around 70 years old, though, rarely, it is seen in
people under age 40. Patients with CLL may be asymptomatic and may initially be diagnosed
by the detection of lymphocytosis on a routine complete blood cell count (1). Sometimes the
patients develop anemia, thrombocytopenia, lymphadenopathy, and/or hepatosplenomegaly (5).
Other cases may present fever, fatigue, night sweats, and weight loss (1). As we describe in a
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previous report (4), chronic lymphocytic leukemia can present
two clinical forms, aggressive and indolent. The worst prognosis
is associated with CD38 expression, high expression levels of
ZAP-70, and the absence of mutations in the immunoglobulin
heavy chain variable (IGHV) genes (4, 6, 7). Discrimination
of patients with different outcomes can be done by finding
chromosomal alterations, which are normally detected in >80%
of cases (4, 8). The most frequent genomic aberration (deletions
at chromosome 13q14) can be detected by FISH analysis. Most
of the CLL patients show constitutively elevated expression
of Bcl-2, indicating a role for resistance to apoptosis in the
disease pathogenesis.
The particular ability of autophagy to promote cell survival
during metabolic stress or cell death as a result of an imbalance in
cell metabolism, where autophagic cellular consumption exceeds
the cellular capacity for synthesis, is a promising avenue for
cancer therapy (9). As described by Bologna et al. (3), autophagy
is activated in leukemia cells upon treatment with different
chemotherapeutic agents, inducing cell death. In particular,
many currently used drugs for CLL, including fludarabine,
dexamethasone, idelalisib, and Bcl-2 antagonists, have been
suggested to have an autophagy-mediated effect (3).
It was proposed that conventional CLL prognostic markers
like genetic mutations, the mutation status of the IGHV, and
expression of ZAP-70 and CD38, have predictive value for the
responses to first-line therapy in CLL (4, 10). Many initiatives
have aimed at integrating all of the prognostic factors defined
previously into a single prognostic score (11, 12). As stated by
Strati et al. (1), it has recently been suggested that “published
evidence is sufficient to recommend that FISH and IGHV
analysis be performed as standard clinical tests for all patients
with newly diagnosed CLL in those countries with the resources
to do so” (1, 13). Recently, there was a report of differential
expression of at least 20 miRs in B cells from progressive CLL
patients compared to non-progressive CLL controls (14). Several
of these miRs promote resistance to apoptosis and/or progression
of neoplastic B cell clones. Therefore, studying cell responses able
to modulate miR expression and cell survival, such as autophagy,
may be important for the search for novel prognostic factors and
molecules (14).
BACKGROUND
We present two cases of progressing CLL; the characteristics of
the patients are summarized in Table 1. Two additional non-
progressing CLL patients are included for comparison purposes.
These patients were included in our previous study (4). Here, we
describe the patients accordingly to onset, diagnosis, prognostic
markers, and evolution.
Patient #1
A 58-year-old man was diagnosed with CLL in February 2008.
At that time, routine analysis showed a total white blood cell
count of 34 × 109/L (normal range: 4.5–10 × 109/L), 82% of
lymphocytes (normal range: 20–45%), with splenomegaly and no
anemia or thrombocytopenia. Lactate dehydrogenase (LDH) and
B2-microglobulin (B2M) values were 312 UI/L and 4.85 mg/L,
respectively (reference values: LDH: 180–450 UI/L; B2M: 0.8–
2.20 mg/L). Flow cytometry analysis revealed a clonal B cell
population with a typical CLL phenotype. Prognostic marker
analysis showed 58% of ZAP-70- and 80% of CD38-positive
cells (15). Thus, a diagnostic of CLL Rai stage II was done, and
the patient was treated with bendamustine from 2009 to 2016
because progressive systemic symptoms were present. At that
moment, genetic markers were: 17p deleted 4.7 %, 11q deleted
62.5%, 13q14 14.4%, and the IGHV gene was unmutated. A
stringent follow-up was adopted until July 2016, when he arrived
at our Center because of progression with lymphadenopathy,
hepatosplenomegaly, and systemic symptoms. At this time, he
received targeted drug treatment with Ibrutinib for 16 months,
achieving partial response. Finally, he progressed to Richter
Syndrome, and the patient died 1 month later.
Patient #2
A 51-year-old man was diagnosed with CLL in February 2010.
At that time, routine analysis showed a total white blood cell
count of 51.7 × 109/L (normal range: 4.5–10 × 109/L), 91% of
lymphocytes (normal range: 20–45%), with hepatosplenomegaly
and no anemia or thrombocytopenia. Lactate dehydrogenase
(LDH) and B2-microglobulin (B2M) values were 257 UI/L and
3.6 mg/L, respectively (reference values: LDH: 180–450 UI/L;
B2M: 0.8–2.20 mg/L). Flow cytometry analysis revealed a clonal
B cell population with a typical CLL phenotype, expressing
prognostic markers ZAP-70 and CD38 (15). Thus, a diagnostic
of CLL Rai stage II was done, and progression was detected
in October 2010. In March 2011, first-line treatment of six
cycles with Fludarabine, Cyclophosphamide, and Rituximab was
administered, followed by two additional cycles in May 2015.
Genetic markers were: 17p deleted 20%, 13q 53.9%, 11q normal,
and the IGHV gene was unmutated. Relapse was observed in
2014 with profuse sweating and progression to stage IIB. In 2016,
further progression to stage IV was observed with weight loss,
hepatosplenomegaly, lymphadenopathy, asthenia, sweating, and
low platelet count. Ibrutinib treatment was initiated in May 2016,
and the patient died in March 2018.
Patients #3 and #4
Patients 3 and 4 presented non-progressing CLL, RAI stages
I and 0, respectively, mutated IGHV gene, and negative for
CD38 and ZAP70. They were diagnosed in 2006 and 2009,
respectively. They subsequently maintained the typical non-
progressive phenotype, and both are still alive (Table 1).
LC3 Expression in Cells From CLL Patients
At the moments of progression of patients 1 and 2, we
evaluated autophagy protein LC3B expression in CLL cells
by flow cytometry (FlowCellectTM, MilliporeSigma, Darmstadt,
Germany). Peripheral blood mononuclear cells (PBMC) from
patients with CLL were cultured in the presence or the absence
of bafilomycin and then stained using antibodies specific for
CD5, CD19, and LC3B. Chronic lymphocytic leukemia B cells
were identified and gated using the combination of CD5 plus
CD19 staining, for the evaluation of LC3B expression. Lipidated
membrane-located LC3B fraction (LC3BII) was accumulated in
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del 17p del 11q Progression
CLL#1 58 2008 II M +/+ UM Yes Yes Yes
CLL#2 51 2010 IIB M +/+ UM Yes No Yes
CLL#3 43 2006 I F –/– MM No Yes No
CLL#4 55 2009 0 M –/– MM Yes Yes No
Chronic lymphocytic leukemia was diagnosed according to standard clinical and laboratory criteria. At the time of analysis, all patients were free from clinically relevant infectious
complications. For all in vitro studies, written and informed consent was obtained from patients in accordance with the Declaration of Helsinki. CLL#1 and CLL#2 represent a subgroup
of patients with adverse prognostic factors, and CLL#3 and CLL#4 represent patients with more favorable prognostic factors.
M, male; F, female; UM, unmutated; MM, mutated.
FIGURE 1 | LC3B expression in CLL cells. (A) PBMC cells from patients with CLL were treated with 25 nM bafilomycin (Baf) or medium (untreated control) for 24 h.
Flow cytometric analysis of LC3B expression in CLL cells is shown. (i) Dot plot of CD19 vs. side scatter (SSC) of B lymphocytes from CLL patients. (ii) Dot plot of
CD19 vs. CD5 shows clonal CLL cells and residual T cells. (iii) Histogram showing LC3B expression (MFI) in clonal B cells treated with Baf and untreated cells. (B)
LC3B index B/M was calculated by dividing MFI of LC3B of CD19+CD5+ (clonal B cells) treated with bafilomycin by MFI of LC3B of untreated clonal B cells (*p <
0.05, unpaired t-test). (C) Automatic population separator (APS) shows two populations: LC3B+ CLL cells from two patients with unmutated IGHV (Purple) and
LC3B+ CLL cells from two patients with mutated IGHV (Green). (D) PBMC cells from all four patients (CLL#1, Patient #1; CLL#2, Patient #2; CLL#3, Patient #3;
CLL#4, Patient #4) were treated with bafilomycin 25 nM for 2 h. After that, MFI of LC3B was determined by flow cytometry, as described in (A).
the presence of bafilomycin (Figure 1A). Samples from non-
progressing (mutated IGHV) patients 3 and 4 were also included
as controls.
We observed higher expression of LC3BII in cells from
unmutated progressing CLL patients compared to the cells
from mutated non-progressing CLL patients (p < 0.05)
(Figure 1B). In addition, using InfinicytTM software, we merged
files of all the patients into one file and then analyzed
immunophenotype-based automatic separation of cell clusters
(automatic population separation, APS) (InfinicytTM software,
Cytognos S.L., Salamanca, Spain) based on LC3BII expression
(Figure 1C). The APS algorithm clearly discriminated two
groups of data corresponding to samples from progressing
and non-progressing CLL patients, respectively (Figure 1C).
This suggests that LC3BII expression may contribute to
the discrimination between progressing and non-progressing
patients. In addition, similar results were obtained when
LC3BII expression was studied in cells from CLL patients
by flow cytometry (Figure 1D) and the classical Western
immunoblotting detection of LC3B (Figure 2A). In the presence
of bafilomycin, increased LC3BII levels were observed in samples
from unmutated progressing CLL patients (Figure 1D). Minimal
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FIGURE 2 | (A) PBMC cells from all four patients (CLL#1, Patient #1; CLL#2, Patient #2; CLL#3, Patient #3; CLL#4, Patient #4) were treated as described in
Figure 1D, then LC3B and β-actin protein levels were examined by immunoblotting. The figure shows image and relative band intensity quantification. The results
were analyzed by t-test. Error bars represent SEM (**p < 0.01). (B) In addition to LC3B and β-actin, p62 and Beclin protein levels were examined by immunoblotting in
new samples from survivor Patients #3 and #4 (CLL#3 and CLL#4, respectively). The results were analyzed by t-test. No significant differences were observed.
LC3BII detection was observed in samples frommutated patients
(CLL#3 and CLL#4) (Figure 1D). In additional experiments, we
analyzed p62/SQSTM1 and Beclin expression in new samples
from survivor (mutated IGHV) patients 3 and 4 by Western
immunoblotting. We did not find significant differences in the
expression levels of autophagy proteins between untreated and
bafilomycin-treated samples (Figure 2B).
It is important to notice that increased LC3BII expression
was detected by Western immunoblotting (Figure 2A) when
the patients progressed but before Ibrutinib treatment. Similar
results were obtained by flow cytometry (Figure 1) after
Ibrutinib treatment.
These results, taken together, suggest that autophagy
activation may correlate with CLL progression beyond
Ibrutinib treatment.
DISCUSSION
Here we found that two patients with progressing CLL showed
increased expression of the autophagy protein LC3B in addition
to positive CD38 and ZAP70 expression and unmutated status
of IGHV.
Autophagy, and autophagy-related proteins (ATG), play a
central role in integrating many stress signals to determine the
fate of cells (16). There are multiple reports in the literature
of autophagy providing resistance to anticancer treatments
in vitro (17–20), but the resistance mechanisms have yet to
be completely determined (16). Autophagy is considered a
fundamental survival mechanism that allows cells to adapt to
a hostile microenvironment through the recycling of cytosolic
molecules in double-membrane vesicles named autophagosomes
(21). This mechanism can be induced by several stressors
blocking both extrinsic and intrinsic apoptotic pathways (21). It
has been described that neoplastic cells can exploit autophagy
to survive under hypoxia and low-nutrient conditions (22, 23).
Recently, it has become evident that combinatory drug therapy
can benefit from the cross-sensitization induced in tumoral cells
by cross-modulation of the molecular pathways targeted by each
drug. For instance, we recently observed that rapamycin, amTOR
inhibitor, enhanced Fludarabine-induced cytotoxicity in CLL B
cells (4). It was reported that pre-treatment of CLL cells with
Bruton’s tyrosine kinase inhibitor Ibrutinib, whether ex vivo or
in vivo in patients, enhances mitochondrial Bcl-2 dependence,
increasing the killing of CLL cells by Venetoclax (24). Similarly,
we observed that cells from patients with progressing CLL treated
in vivo with Ibrutinib were more sensitive to in vitro treatment
with Venetoclax than cells from patients with non-progressing
CLL (data not shown).
Kipps et al. highlighted that the “clinical course of newly
diagnosed CLL is very variable; some patients remain free of
symptoms and are fully active for decades, whereas others
rapidly become symptomatic or develop high-risk disease, which
requires treatment soon after diagnosis and might result in death
due to therapy-related and/or disease-related complications (2).
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However, most patients have a clinical course that is in between
these two extremes.
More robust prognostic markers are provided by newer
techniques, such as flow cytometry, cytogenetics, and molecular
biology” (2). Here, we applied flow cytometry technology to
simultaneously detect autophagy protein LC3B together with
classical phenotypical markers that identify tumoral CLL B
cell clones. In addition, we exploited immunophenotype-based
(including LC3B expression) automatic separation of cell clusters
(APS) to discriminate different groups of data that correlated
with the disease progression and IGHV mutational status of
the patients. Our results suggest that activation of autophagy
flux may correlate with CLL progression even before Ibrutinib
treatment. Kong et al. (25) found increased levels of ATG5 and
Beclin mRNA in a Chinese cohort of CLL patients compared
to healthy controls. However, these results were inconsistent
with the findings by Kristensen et al. (26) showing high
expression of Beclin being associated with more aggressive
disease. The detailed study of the dynamics of autophagosome
formation and disappearance during the autophagic flux may
solve discrepancies in the interpretation of the role of autophagy
in pathogenesis, progression, and therapheutic outcome in CLL.
Autophagy is a very complex response that involves the
expression, modification, association, and degradation of ATG
proteins. Alterations in the expression of autophagy genes
contribute to the tumorigenesis process in numerous types of
cancer during tumor initiation, progression, and development
and to the maintenance of the malignant state (27). The
activation of autophagy flux plays key roles in controlling the
tumor microenvironment and in the therapeutic response (28).
However, in different subtypes of hematopoietic malignancies,
the role of autophagy in cell transformation and the impact
of autophagy on the response to different treatment strategies
remains ambiguous. In this regard, it has been reported that
decreased Bcl-2 levels and an increase in Beclin-1 expression
correlate with a favorable clinical outcome in high-grade B-
cell lymphomas (29, 30). In line with these observations,
it was reported that high expression of LC3 or BECN1 is
associated with a favorable outcome in multiple myeloma (31).
Nevertheless, other studies have demonstrated an opposite role
for the autophagymachinery in diseasemalignancy development,
showing that autophagy activation is required to induce multiple
myeloma cell survival (32, 33). Moreover, autophagy machinery
activation has been shown to be involved in the progression
of other hematopoietic cancers. Indeed, Giatromanolaki et al.
reported that patients with follicular and diffuse large B-
cell lymphomas express high LC3 levels compared to normal
B-cells (34). Considering all of this information, the role of
autophagy in lymphoid malignancies is still debated and might
be subtype-specific. While several studies have addressed the
impact of autophagy in treatment response in several subtypes of
hematopoietic malignancies, further studies are needed to better
understand the effect of changes in the autophagy flux during
disease progression and therapy responses.
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